Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)
by on Tuesday, February 7th, 2012 | No Comments
Condition: Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Intervention: Drug: CO-1686
Sponsor: Clovis Oncology, Inc.
Not yet recruiting – verified February 2012